Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT01186991
First received: August 9, 2010
Last updated: January 19, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2016
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: July 15, 2016
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):